Hydroxyethyl Starch

Generic Name: Hydroxyethyl Starch

Brand Names: Hespan, Hextend, Volulyte, Voluven

Drug Type: Small Molecule

CAS Number: 9005-27-0

Unique Ingredient Identifier: 875Y4127EA

Background: Hydroxyethyl starch (HES/HAES) is a nonionic starch derivative. Hydroxyethyl starches (HES) are synthetic colloids commonly used for fluid resuscitation to replace intravascular volume.

HES is a general term and can be sub-classified according to average molecular weight, molar substitution, concentration, C2/C6 ratio and Maximum Daily Dose.

Indication: An intravenous solution of hydroxyethyl starch is used to prevent shock following severe blood loss caused by trauma, surgery, or other issues.

Associated Conditions: Hypovolaemia

Associated Therapies: Granulocyte yield increase

Clinical Trials

Crystalloids or Colloids for Goal-directed Fluid Therapy With Closed-loop Assistance in Major Surgery

Phase 4

Completed

Conditions: Surgery

Interventions: Drug: Plasmalyte
Drug: Volulyte

First Posted Date: 2014-12-09

Last Posted Date: 2018-01-19

Lead Sponsor: Brugmann University Hospital

Target Recruit Count: 160

Registration Number: NCT02312999

Locations: 🇧🇪
CHU Brugmann, Brussels, Belgium
🇧🇪
Erasme, Brussels, Belgium

Effect of Hydroxyethylstarch 6% 130/0.4 Administration on Renal Function After Cardiac Surgery

Not Applicable

Completed

Conditions: Kidney Function Tests

Interventions: Other: standard volume therapy
Drug: Hydroxyethylstarch 6% 130/0.4

First Posted Date: 2014-12-03

Last Posted Date: 2014-12-03

Lead Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Target Recruit Count: 1564

Registration Number: NCT02306213

Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical Patients

Phase 3

Completed

Conditions: Postoperative Kidney Injury

Interventions: Drug: HES 130/0.4 (Voluven)
Drug: human albumin 5%

First Posted Date: 2014-07-16

Last Posted Date: 2023-02-14

Lead Sponsor: The Cleveland Clinic

Target Recruit Count: 149

Registration Number: NCT02192502

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States

The Mortality and Changes in Quality of Life of Patients Suffering From SAH With Different Hydration Strategies

Phase 4

Completed

Conditions: Subarachnoid Hemorrhage

Interventions: Drug: Lactated Ringer's solution
Drug: Hydroxyethyl starch

First Posted Date: 2014-02-17

Last Posted Date: 2014-02-17

Lead Sponsor: University of Debrecen

Target Recruit Count: 96

Registration Number: NCT02064075

Locations: 🇭🇺
University of Debrecen Medical and Health Science Center Department of Anesthesiology and Intensive Care, Debrecen, Hungary

The Effect of Hydroxyethylstarch 6% 130/0.4 in a Balanced Electrolyte Solution (Volulyte®) Compared to Gelatine (Geloplasma®) on Microvascular Reactivity and Tissue Oxygen Saturation During Haemodilution Measured With Near-infrared Spectroscopy

Not Applicable

Completed

Conditions: Microvascular Reactivity
Tissue Oxygen Saturation

Interventions: Drug: Volulyte 6%
Drug: Geloplasma

First Posted Date: 2014-01-13

Last Posted Date: 2015-04-24

Lead Sponsor: University Hospital, Ghent

Target Recruit Count: 40

Registration Number: NCT02034682

Locations: 🇧🇪
Ghent University Hospital, Ghent, Belgium

Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery

Phase 4

Completed

Conditions: Disorders of Coagulation

Interventions: Drug: Lactated Ringer
Drug: Hydroxyethylstarch

First Posted Date: 2013-12-11

Last Posted Date: 2013-12-11

Lead Sponsor: K. C. Rasmussen

Target Recruit Count: 40

Registration Number: NCT02009033

KOREAN Enhanced RecOvery Strategy for Colorectal Surgery

Not Applicable

Terminated

Conditions: Goal-oriented Fluid Therapy
Colorectal Surgery

Interventions: Drug: Volulyte® (6% HES 130/0.4 in balanced solution)
Other: Combined epidural-general anesthesia (CEGA)
Other: Patient-Controlled Epidural Analgesia (PCEA)

First Posted Date: 2013-06-11

Last Posted Date: 2015-08-07

Lead Sponsor: Duke University

Target Recruit Count: 101

Registration Number: NCT01874730

Locations: 🇰🇷
Samsung Medical Center, Gangnam-Gu, Seoul, Korea, Republic of
🇰🇷
Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea, Republic of
🇰🇷
Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of

Observational Study of Oxygen Delivery During a Fractional Fluid Expansion

Completed

Conditions: Hypovolemia
Impaired Oxygen Delivery
Cardiac Output, Low

Interventions: Drug: hydroxyethylstarch 130/0.4

First Posted Date: 2013-04-08

Last Posted Date: 2014-06-16

Lead Sponsor: University Hospital, Caen

Target Recruit Count: 20

Registration Number: NCT01826253

Locations: 🇫🇷
University Hospital of Caen, Caen, France

Effects of Colloid and Crystalloid on the Microcirculatory Alterations During Off-pump Coronary Artery Bypass Surgery

Not Applicable

Completed

Conditions: Cardiac Surgery

Interventions: Drug: plasmalyte solution
Drug: Hextend

First Posted Date: 2012-10-24

Last Posted Date: 2016-06-16

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 120

Registration Number: NCT01713166

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Fluid Resuscitation in Patients Suffering From Burns Injury

Phase 4

Terminated

Conditions: Burns

Interventions: Drug: Volulyte
Drug: Human Serum Albumin

First Posted Date: 2012-09-21

Last Posted Date: 2014-06-26

Lead Sponsor: Fresenius Kabi

Target Recruit Count: 11

Registration Number: NCT01689506

Locations: 🇬🇧
University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre, Birmingham, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy